Varicella Zoster vaccination in hemodialysis patients: The state of the art

Varicella Zoster Virus (VZV) infection is a common childhood exanthematous disease, which in adults and immunocompromised people may result in severe neurologic complications. Up to one-third of infected subjects may have VZV clinical reactivation particularly if immunocompromised. Patients affected...

Full description

Saved in:
Bibliographic Details
Main Authors: Laura Gobbi, Francesca Katiana Martino, Elena Sgrò, Federico Nalesso, Lorenzo A. Calo’
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2023.2286689
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850231654885359616
author Laura Gobbi
Francesca Katiana Martino
Elena Sgrò
Federico Nalesso
Lorenzo A. Calo’
author_facet Laura Gobbi
Francesca Katiana Martino
Elena Sgrò
Federico Nalesso
Lorenzo A. Calo’
author_sort Laura Gobbi
collection DOAJ
description Varicella Zoster Virus (VZV) infection is a common childhood exanthematous disease, which in adults and immunocompromised people may result in severe neurologic complications. Up to one-third of infected subjects may have VZV clinical reactivation particularly if immunocompromised. Patients affected by end-stage renal disease on hemodialysis present immunodepression that contributes to their higher incidence of VZV infections and reactivation. While antiviral treatment in these patients shows low efficacy, the prevention of VZV through vaccination avoids the primary infection and the risk of reactivation. Two VZV vaccines are currently available: the live attenuate Zoster Vaccine (LZV) and a Recombinant Zoster Vaccine (RZV), with the latter appearing to provide greater efficacy. Given the higher incidence of VZV infection and reactivation, the lesser response to antivirals and the lower impact of VZ vaccine in hemodialysis patients in terms of side effects, a higher diffusion of VZV vaccination should be promoted by nephrologists in these patients in particular in those with future transplant opportunities.
format Article
id doaj-art-5c7f64a6d50f4e08a411df8676654e76
institution OA Journals
issn 2164-5515
2164-554X
language English
publishDate 2023-12-01
publisher Taylor & Francis Group
record_format Article
series Human Vaccines & Immunotherapeutics
spelling doaj-art-5c7f64a6d50f4e08a411df8676654e762025-08-20T02:03:27ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2023-12-0119310.1080/21645515.2023.2286689Varicella Zoster vaccination in hemodialysis patients: The state of the artLaura Gobbi0Francesca Katiana Martino1Elena Sgrò2Federico Nalesso3Lorenzo A. Calo’4Nephrology, Dialysis and Transplantation Unit, Department of Medicine, University of Padova, Padova, ItalyNephrology, Dialysis and Transplantation Unit, Department of Medicine, University of Padova, Padova, ItalyNephrology, Dialysis and Transplantation Unit, Department of Medicine, University of Padova, Padova, ItalyNephrology, Dialysis and Transplantation Unit, Department of Medicine, University of Padova, Padova, ItalyNephrology, Dialysis and Transplantation Unit, Department of Medicine, University of Padova, Padova, ItalyVaricella Zoster Virus (VZV) infection is a common childhood exanthematous disease, which in adults and immunocompromised people may result in severe neurologic complications. Up to one-third of infected subjects may have VZV clinical reactivation particularly if immunocompromised. Patients affected by end-stage renal disease on hemodialysis present immunodepression that contributes to their higher incidence of VZV infections and reactivation. While antiviral treatment in these patients shows low efficacy, the prevention of VZV through vaccination avoids the primary infection and the risk of reactivation. Two VZV vaccines are currently available: the live attenuate Zoster Vaccine (LZV) and a Recombinant Zoster Vaccine (RZV), with the latter appearing to provide greater efficacy. Given the higher incidence of VZV infection and reactivation, the lesser response to antivirals and the lower impact of VZ vaccine in hemodialysis patients in terms of side effects, a higher diffusion of VZV vaccination should be promoted by nephrologists in these patients in particular in those with future transplant opportunities.https://www.tandfonline.com/doi/10.1080/21645515.2023.2286689Varicella Zoster virus infectionVaricella Zoster virus reactivationZoster vaccineshemodialysisend stage renal disease
spellingShingle Laura Gobbi
Francesca Katiana Martino
Elena Sgrò
Federico Nalesso
Lorenzo A. Calo’
Varicella Zoster vaccination in hemodialysis patients: The state of the art
Human Vaccines & Immunotherapeutics
Varicella Zoster virus infection
Varicella Zoster virus reactivation
Zoster vaccines
hemodialysis
end stage renal disease
title Varicella Zoster vaccination in hemodialysis patients: The state of the art
title_full Varicella Zoster vaccination in hemodialysis patients: The state of the art
title_fullStr Varicella Zoster vaccination in hemodialysis patients: The state of the art
title_full_unstemmed Varicella Zoster vaccination in hemodialysis patients: The state of the art
title_short Varicella Zoster vaccination in hemodialysis patients: The state of the art
title_sort varicella zoster vaccination in hemodialysis patients the state of the art
topic Varicella Zoster virus infection
Varicella Zoster virus reactivation
Zoster vaccines
hemodialysis
end stage renal disease
url https://www.tandfonline.com/doi/10.1080/21645515.2023.2286689
work_keys_str_mv AT lauragobbi varicellazostervaccinationinhemodialysispatientsthestateoftheart
AT francescakatianamartino varicellazostervaccinationinhemodialysispatientsthestateoftheart
AT elenasgro varicellazostervaccinationinhemodialysispatientsthestateoftheart
AT federiconalesso varicellazostervaccinationinhemodialysispatientsthestateoftheart
AT lorenzoacalo varicellazostervaccinationinhemodialysispatientsthestateoftheart